Insulin resistance and vascular disease
Date
2004, 2004
Authors
Maritz F.J.
Maritz F.J.
Journal Title
Journal ISSN
Volume Title
Publisher
Abstract
The insulin resistance syndrome comprises a typical cluster of cardiovascular risk factors and is predicted to increase dramatically over the next few decades. The disease process starts many years before the condition is clinically obvious and targets primarily the cardiovascular system. The pathogenesis involves a complex interplay between all the associated cardiovascular risk factors but endothelial dysfunction plays a major role. Management of these patients involves management of all the associated risk factors and should be aimed primarily at early detection and the prevention of vascular morbidity and mortality in the short and long term.
The insulin resistance syndrome comprises a typical cluster of cardiovascular risk factors and is predicted to increase dramatically over the next few decades. The disease process starts many years before the condition is clinically obvious and targets primarily the cardiovascular system. The pathogenesis involves a complex interplay between all the associated cardiovascular risk factors but endothelial dysfunction plays a major role. Management of these patients involves management of all the associated risk factors and should be aimed primarily at early detection and the prevention of vascular morbidity and mortality in the short and long term.
The insulin resistance syndrome comprises a typical cluster of cardiovascular risk factors and is predicted to increase dramatically over the next few decades. The disease process starts many years before the condition is clinically obvious and targets primarily the cardiovascular system. The pathogenesis involves a complex interplay between all the associated cardiovascular risk factors but endothelial dysfunction plays a major role. Management of these patients involves management of all the associated risk factors and should be aimed primarily at early detection and the prevention of vascular morbidity and mortality in the short and long term.
Description
Keywords
albumin; dipeptidyl carboxypeptidase inhibitor; fibric acid derivative; glucose; homocysteine; hydroxymethylglutaryl coenzyme A reductase inhibitor; insulin; low density lipoprotein cholesterol; metformin; oral antidiabetic agent; peroxisome proliferator activated receptor alpha; peroxisome proliferator activated receptor gamma; pioglitazone; placebo; plasminogen activator inhibitor 1; proteinase inhibitor; ramipril; rosiglitazone; article; atherosclerosis; behavior modification; cardiovascular risk; cardiovascular system; clinical trial; coronary artery disease; diabetic angiopathy; diagnostic accuracy; disease course; dyslipidemia; early diagnosis; endothelium cell; exercise; human; hyperglycemia; hyperhomocysteinemia; impaired glucose tolerance; insulin resistance; lifestyle; metabolic syndrome X; microalbuminuria; morbidity; mortality; non insulin dependent diabetes mellitus; pathogenesis; patient compliance; prediction; primary prevention; rhabdomyolysis; risk factor; smoking cessation; vascular disease, albumin, dipeptidyl carboxypeptidase inhibitor, fibric acid derivative, glucose, homocysteine, hydroxymethylglutaryl coenzyme A reductase inhibitor, insulin, low density lipoprotein cholesterol, metformin, oral antidiabetic agent, peroxisome proliferator activated receptor alpha, peroxisome proliferator activated receptor gamma, pioglitazone, placebo, plasminogen activator inhibitor 1, proteinase inhibitor, ramipril, rosiglitazone, article, atherosclerosis, behavior modification, cardiovascular risk, cardiovascular system, clinical trial, coronary artery disease, diabetic angiopathy, diagnostic accuracy, disease course, dyslipidemia, early diagnosis, endothelium cell, exercise, human, hyperglycemia, hyperhomocysteinemia, impaired glucose tolerance, insulin resistance, lifestyle, metabolic syndrome X, microalbuminuria, morbidity, mortality, non insulin dependent diabetes mellitus, pathogenesis, patient compliance, prediction, primary prevention, rhabdomyolysis, risk factor, smoking cessation, vascular disease
Citation
Journal of Endocrinology, Metabolism and Diabetes of South Africa
9
2
Journal of Endocrinology, Metabolism and Diabetes of South Africa
9
2
9
2
Journal of Endocrinology, Metabolism and Diabetes of South Africa
9
2